ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a copy of advertisement related to notice of loss of share certificate(s) published by the Company on behalf of the registered shareholder(s) in Business Standard (English edition) on 23rd June, 2022. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Update On India Branded Business
With reference to the captioned matter, an update on India Branded Business is enclosed. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Business Update On F.Y. 2021-22
This is to inform the exchange that the Business Update on Financial Year 2021-22 is uploaded on the website of the Company and the same can be accessed at: https://alembicpharmaceuticals.com/Business%20Update%20on%20Financial%20Year%2021-22.pdf We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Disclosure of Voting results of Court Convened Meeting (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Alembic Pharmaceuticals Ltd has informed BSE regarding the details of Voting results of Court Convened Meeting, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here ALEMBIC PHARMACEUTICALS LTD. - 533573 - Declaration Of Voting Results For The Meeting Of The Equity Shareholders Of The Company Convened As Per The Directions Of Hon'Ble National Company Law Tribunal, Ahmedabad Bench ('NCLT')
With reference to the captioned matter and above referred intimation, we would like to inform that the Meeting of the Equity Shareholders of the Company was held on 14th June, 2022 through Video Conferencing ('VC') / Other Audio Visual Means ('OAVM'). Please find enclosed herewith: a) Voting Results as required under Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. b) Consolidated Scrutinizers' Report on E-voting (without Annexure) as per the provisions of Section 108 of the Companies Act, 2013 read with Companies (Management and Administration), Rules, 2014. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Submission Of Consolidated Scrutinizer'S Report (Without Annexure) For The Meeting Of The Secured Creditors, Unsecured Creditors And Equity Shareholders Of The Company Convened As Per The Directions Of Hon'Ble National Company Law Tribunal, Ahmedabad Bench ('NCLT')
With reference to the captioned matter and above referred intimations, we would like to inform that the Meetings of the Secured Creditors, Unsecured Creditors and Equity Shareholders of the Company were held on 14th June, 2022 through Video Conferencing ('VC') / Other Audio Visual Means ('OAVM'). Please find enclosed herewith: a) Consolidated Scrutinizers' Report on E-voting for the meeting of the Secured Creditors of the Company. b) Consolidated Scrutinizers' Report on E-voting for the meeting of the Unsecured Creditors of the Company. c) Consolidated Scrutinizers' Report on E-voting for the meeting of the Equity Shareholders of the Company. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Meeting Updates
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith proceedings of the Meeting of the Secured Creditors, Unsecured Creditors and Equity Shareholders of the Company held on 14th June, 2022. We request you to kindly take the same on record.
Alembic Pharma gets USFDA nod for cancer treatment drug in US market
Alembic Pharmaceuticals on Friday said it has received approval from the US health regulator to market Dasatinib tablets, used to treat certain types of cancers, in the American market ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
With reference to the captioned subject, this is to inform the exchange that the Company has received US Food & Drug Administration (USFDA) Tentative Approval for Dasatinib Tablets, 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg. Please find enclosed herewith our press release. We request you to kindly take the same on record. Alembic Pharma gets USFDA approval to market Pirfenidone tablets
Alembic Pharmaceuticals said it has received approval from the US health regulator to market Pirfenidone tablets used to treat lung disease in the American market.